{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/collaborative-delivery-advances-rare-metabolic-disease-program-apac-biotech#webpage",
"url": "https://www.fortrea.com/insights/collaborative-delivery-advances-rare-metabolic-disease-program-apac-biotech",
"name": "Collaborative Delivery Advances a Rare Metabolic Disease Program for an APAC Biotech",
"description": "Explore this Fortrea Case Study highlighting how strategic regulatory engagement and patient advocacy collaboration helped advance a Phase II clinical trial for an ultra-rare metabolic disease across the Asia-Pacific region. The study faced significant challenges due to limited patient availability, pediatric enrollment restrictions, and evolving regulatory expectations that threatened recruitment timelines and overall study progression. To address these barriers, Fortrea partnered closely with the study sponsor, investigators, regulatory agencies, and patient advocacy organizations to develop a coordinated strategy focused on stakeholder alignment, scientific communication, and patient-centered planning. The case study demonstrates how proactive regulatory engagement helped address concerns surrounding pediatric participation while advocacy group collaboration improved awareness and support within the rare disease community. Through cross-functional leadership, regional clinical development expertise, and a tailored enrollment strategy, Fortrea helped accelerate patient recruitment, strengthen stakeholder collaboration, and support the successful advancement of a complex ultra-rare metabolic disease clinical trial. The resource highlights the critical role of regulatory strategy, patient advocacy partnerships, pediatric research expertise, and collaborative clinical development approaches in overcoming enrollment challenges and advancing rare disease research for underserved patient populations."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Collaborative Delivery Advances a Rare Metabolic Disease Program for an APAC Biotech",
"item": "https://www.fortrea.com/insights/collaborative-delivery-advances-rare-metabolic-disease-program-apac-biotech"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/collaborative-delivery-advances-rare-metabolic-disease-program-apac-biotech#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/collaborative-delivery-advances-rare-metabolic-disease-program-apac-biotech#webpage"
},
"headline": "Accelerating Pediatric Enrollment in an Ultra-Rare Metabolic Disease Clinical Trial | Fortrea Case Study",
"description": "Explore this Fortrea Case Study highlighting how strategic regulatory engagement and patient advocacy collaboration helped advance a Phase II clinical trial for an ultra-rare metabolic disease across the Asia-Pacific region. The study faced significant challenges due to limited patient availability, pediatric enrollment restrictions, and evolving regulatory expectations that threatened recruitment timelines and overall study progression. To address these barriers, Fortrea partnered closely with the study sponsor, investigators, regulatory agencies, and patient advocacy organizations to develop a coordinated strategy focused on stakeholder alignment, scientific communication, and patient-centered planning. The case study demonstrates how proactive regulatory engagement helped address concerns surrounding pediatric participation while advocacy group collaboration improved awareness and support within the rare disease community. Through cross-functional leadership, regional clinical development expertise, and a tailored enrollment strategy, Fortrea helped accelerate patient recruitment, strengthen stakeholder collaboration, and support the successful advancement of a complex ultra-rare metabolic disease clinical trial. The resource highlights the critical role of regulatory strategy, patient advocacy partnerships, pediatric research expertise, and collaborative clinical development approaches in overcoming enrollment challenges and advancing rare disease research for underserved patient populations.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-04-28",
"dateModified": "2026-04-28",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-04/rare-metabolic-disease-apac-case-study.pdf",
"encodingFormat": "application/pdf"
}
}
]
}